The estimated Net Worth of Jonathan Zalevsky is at least 43.3 百万$ dollars as of 19 August 2024. Jonathan Zalevsky owns over 6,866 units of Nektar Therapeutics stock worth over 313,505$ and over the last 5 years he sold NKTR stock worth over 3,780,624$. In addition, he makes 39,242,200$ as Chief Research and Development Officer at Nektar Therapeutics.
Sign up
Jonathan Zalevsky NKTR stock SEC Form 4 insiders trading
Jonathan has made over 22 trades of the Nektar Therapeutics stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 6,866 units of NKTR stock worth 8,788$ on 19 August 2024.
The largest trade he's ever made was selling 73,716 units of Nektar Therapeutics stock on 18 August 2022 worth over 342,779$. On average, Jonathan trades about 12,945 units every 62 days since 2019. As of 19 August 2024 he still owns at least 250,804 units of Nektar Therapeutics stock.
You can see the complete history of Jonathan Zalevsky stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Jonathan Zalevsky biography
Dr. Jonathan Zalevsky Ph.D. serves as Chief Research and Development Officer of the Company. Dr. Zalevsky served as our Senior Vice President, Biology and Preclinical Development from April 2017 through November 2017 and served as our Senior Vice President, Research and Chief Science Officer from November 2017 to October 2019. From July 2015 through April 2017, Dr. Zalevsky served as our Vice President, Biology and Preclinical Development. Prior to joining Nektar, Dr. Zalevsky was Global Vice President and Head of the Inflammation Drug Discovery Unit at Takeda Pharmaceuticals. Prior to working at Takeda, Dr. Zalevsky held a number of research and development positions at Xencor, Inc. Dr. Zalevsky received his Ph.D. in Biochemistry from the Tetrad Program at the University of California, San Francisco. He received dual bachelor degrees in Biochemistry and Molecular, Cellular and Developmental Biology from the University of Colorado at Boulder.
What is the salary of Jonathan Zalevsky?
As the Chief Research and Development Officer of Nektar Therapeutics, the total compensation of Jonathan Zalevsky at Nektar Therapeutics is 39,242,200$. There are no executives at Nektar Therapeutics getting paid more.
How old is Jonathan Zalevsky?
Jonathan Zalevsky is 45, he's been the Chief Research and Development Officer of Nektar Therapeutics since 2019. There are 16 older and 2 younger executives at Nektar Therapeutics. The oldest executive at Nektar Therapeutics is Dr. Brian L. Kotzin, 72, who is the Sr. VP of Clinical Devel. & Head of Immunology.
What's Jonathan Zalevsky's mailing address?
Jonathan's mailing address filed with the SEC is C/O NEKTAR THERAPEUTICS, 455 MISSION BAY BLVD SOUTH, SAN FRANCISCO, CA, 94158.
Insiders trading at Nektar Therapeutics
Over the last 21 years, insiders at Nektar Therapeutics have traded over 57,608,493$ worth of Nektar Therapeutics stock and bought 90,000 units worth 1,628,550$ . The most active insiders traders include Howard W Robin、Gil M Labrucherie、John Nicholson. On average, Nektar Therapeutics executives and independent directors trade stock every 11 days with the average trade being worth of 36,648$. The most recent stock trade was executed by Jonathan Zalevsky on 19 August 2024, trading 6,866 units of NKTR stock currently worth 8,788$.
What does Nektar Therapeutics do?
nektar therapeutics is a leading biopharmaceutical company developing a robust pipeline of novel therapeutics based on its advanced polymer conjugate chemistry technology platform. nektar also partners with the top biopharmaceutical companies to bring new products to market. to date, nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies.
What does Nektar Therapeutics's logo look like?
Complete history of Jonathan Zalevsky stock trades at Nektar Therapeutics
Nektar Therapeutics executives and stock owners
Nektar Therapeutics executives and other stock owners filed with the SEC include:
-
Jonathan Zalevsky,
Chief Research and Development Officer -
Howard Robin,
President, Chief Executive Officer, Director -
Gilbert Labrucherie,
Chief Financial Officer, Chief Operating Officer, Senior Vice President -
John Northcott,
Senior Vice President and Chief Commercial Officer -
Howard W. Robin,
CEO, Pres & Director -
Jillian Thomsen,
Senior Vice President - Finance, Chief Accounting Officer -
Gilbert M. Labrucherie J.D.,
Sr. VP, CFO & COO -
Dr. Jonathan Zalevsky,
Chief R&D Officer -
John P. Northcott,
Sr. VP & Chief Commercial Officer -
Mark A. Wilson,
Sr. VP, Gen. Counsel & Sec. -
Myriam Curet,
Independent Director -
Robert Chess,
Independent Chairman of the Board -
Roy Whitfield,
Lead Independent Director -
R. Scott Greer,
Independent Director -
Karin Eastham,
Independent Director -
Jeff Ajer,
Independent Director -
Dr. Brian L. Kotzin,
Sr. VP of Clinical Devel. & Head of Immunology -
Dr. Mary Tagliaferri L.Ac., M.D.,
Sr. VP & Exec. Clinical Fellow -
Jennifer Ruddock,
Sr. VP of Strategy & Corp. Affairs -
Robert Bacci,
Sr. VP of HR and Facilities -
Jillian B. Thomsen,
Sr. VP of Fin. & Chief Accounting Officer -
Lutz Lingnau,
Director -
Dennis L Winger,
Director -
Ivan P. Gergel,
SVP Drug Development & CMO -
Maninder Hora,
SVP Pharma Dev and Mfg -
Christopher A Kuebler,
Director -
Joseph J Krivulka,
Director -
Melvin Perelman,
Director -
Ajit Gill,
CEO & President -
Track Capital, Lp Deep Trac...,
-
Randall W Moreadith,
SVP Drug Development -
Bharat M Chowrira,
COO & Head of PEGylation BU -
Robert Medve,
Chief Medical Officer -
Nevan C Elam,
General Counsel and Secretary -
Timothy Harkness,
SVP & Chief Financial Officer -
John Stuart Patton,
Chief Scientific Officer -
Irwin Lerner,
Director -
Michael A/Ca Brown,
Director -
Masuoka K. Lorianne,
SVP & Chief Medical Officer -
Susan Wang,
Director -
Rinko Ghosh,
SVP & Chief Business Officer -
David Johnston,
SVP, Research & Development -
Ajay Bansal,
CFO, VP Finance & Admin -
Hoyoung Huh,
Chief Operating Officer -
J Milton Harris,
President of Nektar AL -
James B Glavin,
Director -
John Nicholson,
SVP & Chief Operating Officer -
Stephen K Doberstein,
SVP & Chief Scientific Officer -
Gil M Labrucherie,
SVP, COO & CFO -
Diana Brainard,
Director -
Mark Andrew Wilson,
Chief Legal Officer